Korean J Gastroenterol.  2013 Nov;62(5):261-262. 10.4166/kjg.2013.62.5.261.

The Usefulness of Fecal Calprotectin in Differentiating between Functional and Organic Bowel Diseases: Application in Pediatric Constipation Patients

• Hong SN

• KMID: 1775731
• DOI: http://doi.org/10.4166/kjg.2013.62.5.261

Abstract

No abstract available.

MeSH Terms

Constipation/*diagnosis
Female
Hirschsprung Disease/*diagnosis
Humans
Leukocyte L1 Antigen Complex/*analysis
Male
Leukocyte L1 Antigen Complex

Reference

References

1. Lee KM. Fecal biomarkers in inflammatory bowel disease. Intest Res. 2013; 11:73–78.

2. Desai D, Faubion WA, Sandborn WJ. Review article: biological activity markers in inflammatory bowel disease. Aliment Pharmacol Ther. 2007; 25:247–255.

3. Konikoff MR, Denson LA. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm Bowel Dis. 2006; 12:524–534.

4. von Roon AC, Karamountzos L, Purkayastha S, et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol. 2007; 102:803–813.

5. Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology. 2011; 140:1817–1826.

6. Bunn SK, Bisset WM, Main MJ, Golden BE. Fecal calprotectin as a measure of disease activity in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2001; 32:171–177.

7. Canani RB, Terrin G, Rapacciuolo L, et al. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Dig Liver Dis. 2008; 40:547–553.

8. Tibble J, Sigthorsson G, Foster R, Sherwood R, Fagerhol M, Bjarnason I. Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Gut. 2001; 49:402–408.

9. van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic metaanalysis. BMJ. 2010; 341:c3369.

10. Hoff G, Grotmol T, Thiis-Evensen E, Bretthauer M, Gondal G, Vatn MH. Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT). Gut. 2004; 53:1329–1333.

11. Mahjoub FE, Zahedi N, Ashjai B, et al. Role of fecal calprotectin in differentiating between Hirschsprung's disease and functional constipation. Korean J Gastroenterol. 2013; 62:288–291.

12. Teitelbaum DH, Qualman SJ, Caniano DA. Hirschsprung's disease. Identification of risk factors for enterocolitis. Ann Surg. 1988; 207:240–244.

13. Wassell J, Wallage M, Brewer E. Evaluation of the Quantum Blue^Ⓡ rapid test for faecal calprotectin. Ann Clin Biochem. 2012; 49:55–58.